"Novo Nordisk-partnered drug shows 19.7% weight loss in Phase II trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Add Yahoo as a preferred source to see more of our stories on Google. MetaVia's DA-1726 is a dual OXM analogue agonist that functions as a glucagon-like peptide-1 receptor (GLP-1RA) and glucagon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results